Vets hail vac­cine au­tho­ri­sa­tion

Fish Farmer - - United Kingdom News -

PHAR­MAQ has been granted a new mar­ket­ing au­tho­ri­sa­tion in the UK and Ire­land for its mul­ti­com­po­nent vac­cine con­tain­ing Moritella com­po­nent.

The Al­pha Ject mi­cro 6 vac­cine, a POM-V (pre­scrip­tion only medicine – vet­eri­nar­ian), is in­di­cated for use in At­lantic salmon to re­duce mor­tal­ity caused by in­fec­tions with Aeromonas salmoni­cida (fu­run­cu­lo­sis) Vib­rio salmoni­cida (cold­wa­ter vib­rio­sis), Li­s­tonella an­guil­larum serotype O1 and O2 (vib­rio­sis), Moritella vis­cosa (win­ter sore) and IPNV (in­fec­tious pan­cre­atic necro­sis).

Up un­til now, vet­eri­nar­i­ans wish­ing to pre­scribe this vac­cine for Scot­tish fish have had to do so with au­tho­ri­sa­tion from the Vet­eri­nary Medicines Direc­torate through the is­sue of a Spe­cial Im­port Cer­tifi­cate.(SIC).With the re­moval of the SIC re­quire­ment, un­der which 50 mil­lion doses have hith­erto been de­ployed in the UK alone, Phar­maq will be able to sup­ply the lo­cal in­dus­try with the only Moritella com­po­nent vac­cine that en­joys a full MA in the UK and Ire­land.

Al­pha Ject mi­cro 1PD, also a POM-V medicine, al­ready en­joys a full MA in the UK and Ire­land.This con­tains Salmon Pan­creas Dis­ease Virus (SPDV) for ac­tive im­mu­ni­sa­tion of At­lantic salmon to re­duce clin­i­cal signs (heart le­sions and pan­creas le­sions), vi­raemia, vi­ral shed­ding and mor­tal­ity from in­fec­tion with SPDV (pan­creas dis­ease).

It is doc­u­mented for com­bined use with Al­pha Ject mi­cro 6, thus the two vac­cines can pro­vide a flex­i­ble so­lu­tion for vac­ci­na­tion of salmon.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.